Ultragenyx Pharma (RARE) Misses Q1 EPS by 43c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.19), $0.43 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $79.9 million versus the consensus estimate of $83.65 million.

Cash balance of approximately $814 million as of March 31, 2022

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Five Point Holdings, LLC (FPH) Reports Q1 EPS of $0.03
• Community West Bancshares (CWBC) Tops Q1 EPS by 7c